Table 3.

Univariate and multivariate analyses of disease- or progression-free survival (N = 68, 26 progression events).

	DFS/PFS
	Univariate Analysis			Multivariate Analysis
Characteristic	HR	95% CI	p	HR	95% CI	p
Male (vs. female)	0.570	0.258-1.259	0.164	0.362	0.122-1.073	0.067
Age (per year)	2.267	0.952-5.397	0.064	0.784	0.214-2.872	0.713
SCLC (vs. NSCLC)	12.482	4.440-35.095	0.000	5.516	1.510-20.140	0.010
Tumor size(cm) ≥2.79(vs. <2.79)	1.596	0.734-3.470	0.238
T3+T4 (vs. T1+T2)	2.695	1.231-5.899	0.013	0.612	0.142-2.645	0.511
Lymph node metastatic yes (vs. no)	1.937	0.893-4.201	0.094	0.816	0.228-2.918	0.755
Metastasis yes (vs. no)	1.040	0.416-2.597	0.933
Clinical stage others (vs. I)	3.014	1.202-7.554	0.019	3.070	0.457-20.634	0.249
Systemic therapy (vs. surgery)	8.476	1.147-62.611	0.036	2.986	0.351-25.417	0.317
NE(x109/L) ≥6.65 (vs. <6.65)	0.616	0.231-1.641	0.333
LC(x109/L) ≥1.72 (vs. <1.72)	0.206	0.062-0.686	0.010	0.383	0.101-1.455	0.159
PLT(x109/L) ≥190 (vs. <190)	2.192	0.656-7.314	0.202
dNLR≥2.46 (vs. <2.46)	5.105	2.235-11.661	<0.001	1.852	0.672-5.100	0.233
PLR≥171.5 (vs. <171.5)	2.149	0.972-4.751	0.059	1.965	0.673-5.738	0.217
NLR≥1.93 (vs. <1.93)	4.388	1.035-18.609	0.045	2.220	0.420-11.725	0.348
FR+-CTC(Fu/3ml) ≥9.75(vs. <9.75)	3.861	1.674-8.908	0.002	3.039	1.111-8.310	0.030

Values in bold mean p<0.05.